Advanced/Metastatic Clinical Trials

30 recruitingLast updated: June 17, 2026

There are 30 actively recruiting advanced/metastatic clinical trials across 21 countries. Studies span Phase 1, Phase 2, Early Phase 1, Phase 3. Top locations include Houston, Texas, United States, Nashville, Tennessee, United States, Denver, Colorado, United States. Updated daily from ClinicalTrials.gov.


Advanced/Metastatic Trials at a Glance

30 actively recruiting trials for advanced/metastatic are listed on ClinicalTrialsFinder across 6 cities in 21 countries. The largest study group is Phase 1 with 22 trials, with the heaviest enrollment activity in Houston, Nashville, and Denver. Lead sponsors running advanced/metastatic studies include Beijing Biotech, Pfizer, and Shanghai Henlius Biotech.

Browse advanced/metastatic trials by phase

Treatments under study

About Advanced/Metastatic Clinical Trials

Looking for clinical trials for Advanced/Metastatic? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Advanced/Metastatic trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Advanced/Metastatic clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 30 trials

Recruiting
Phase 1Phase 2

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

Locally Advanced/Metastatic Solid Tumors
Crescent Biopharma, Inc.290 enrolled17 locationsNCT07335497
Recruiting
Phase 2

A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Advanced/Metastatic Non-Small Cell Lung Cancer
Regeneron Pharmaceuticals300 enrolled10 locationsNCT07154290
Recruiting
Phase 1

A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation

Advanced/Metastatic Colorectal Adenocarcinoma
Bayer130 enrolled21 locationsNCT07535112
Recruiting
Phase 1Phase 2

Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC

Non-small Cell Lung CancerAdvanced/Metastatic
Beijing Biotech60 enrolled1 locationNCT07641023
Recruiting
Phase 1Phase 2

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

Urothelial CarcinomaUrothelial CancerAdvanced/Metastatic Urothelial Cancer
Pfizer132 enrolled50 locationsNCT07421700
Recruiting
Phase 1Phase 2

Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

Non-small Cell Lung CancerCarcinoma, Non-Small Cell LungAdvanced/Metastatic Non-Small Cell Lung Cancer
Pfizer162 enrolled45 locationsNCT07227298
Recruiting
Phase 1Phase 2

A Phase I/II of HRS-6719 in Patients With Advanced/Metastatic Solid Tumors

Advanced/Metastatic Solid Tumors
Shandong Suncadia Medicine Co., Ltd.120 enrolled2 locationsNCT06922357
Recruiting
Phase 1

A Phase I Clinical Study of HLX316 in Participants With Advanced/Metastatic Solid Tumors

Advanced/Metastatic Solid Tumors
Shanghai Henlius Biotech41 enrolled5 locationsNCT07541534
Recruiting
Phase 1

A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors

Advanced/Metastatic Malignant Solid Tumors
Shanghai Henlius Biotech367 enrolled10 locationsNCT06115642
Recruiting
Phase 2

Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer

HER2-positive Metastatic Breast CancerAdvanced/Metastatic Breast Cancer
Sun Yat-sen University57 enrolled1 locationNCT07610720
Recruiting
Phase 2

Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma

Soft Tissue SarcomaPembrolizumabPhase 2+2 more
M.D. Anderson Cancer Center20 enrolled1 locationNCT07283731
Recruiting
Phase 1

A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors

Advanced/Metastatic Solid Tumors
Antengene Biologics Limited156 enrolled22 locationsNCT05718895
Recruiting
Phase 1

A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors

Advanced/Metastatic Solid Tumors
DualityBio Inc.233 enrolled6 locationsNCT07141706
Recruiting
Phase 1

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

Esophageal CancerPancreatic CancerUrothelial Carcinoma+10 more
Pfizer310 enrolled28 locationsNCT07090499
Recruiting
Phase 1Phase 2

Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC

Triple-Negative Breast CancerHER2-positive Breast CancerBreast Cancer (Advanced/Metastatic)
Beijing Biotech60 enrolled1 locationNCT07510802
Recruiting

Analysis of Circulating Tumor DNA (ctDNA) in HER2-low Advanced/Metastatic Breast Cancer

Advanced/Metastatic Breast Cancer
European Institute of Oncology30 enrolled1 locationNCT06706557
Recruiting
Phase 1Phase 2

Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC

Non-small Cell Lung CancerAdvanced/Metastatic NSCLC
Beijing Biotech48 enrolled1 locationNCT07467863
Recruiting
Early Phase 1

A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors

NSCLCAdvanced/Metastatic Solid Tumors
Shanghai Henlius Biotech254 enrolled2 locationsNCT07274813
Recruiting
Phase 1Phase 2

Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors

Advanced/Metastatic Solid Tumors
CSPC Megalith Biopharmaceutical Co.,Ltd.820 enrolled1 locationNCT07415863
Recruiting

Praegnant Breast Cancer: Early/Advanced/Metastatic

Breast Cancer (Early Breast Cancer)Advanced/Metastatic Breast Cancer
University Hospital Tuebingen13,500 enrolled61 locationsNCT02338167